



Federal Employee Program.

ZORTRESS (everolimus)

Preferred product: generic everolimus

This policy does not apply to generic everolimus

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Zortress (everolimus) inhibits antigenic and interleukin (IL-2 and IL-5) stimulated activation and proliferation of T and B lymphocytes. It is also an mTOR inhibitor. In models, Zortress effectively reduced kidney allograft rejection resulting in prolonged graft survival (1).

Regulatory Status

FDA-approved indication: Zortress is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney or liver transplant (1).

Summary

Zortress (everolimus) is an mTOR inhibitor immunosuppressant used for the prophylaxis of organ rejection in patients who received a kidney or liver transplant (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Zortress while maintaining optimal therapeutic outcomes.

References

1. Zortress [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2024.